E-DRUG: EMA recommends withdrawal of rosiglitazone, long overdue
---------------------------------------
At long last, the European Medicines Agency has decided to recommend the withdrawal of rosiglitazone-based medicines (Avandia°, Avandamet°, Avaglim°), due to serious cardiovascular adverse effects.
Ever since the launch of rosiglitazone in 2002, Prescrire has been recommending against its use, due to this risk (see http://english.prescrire.org/en/
Prescrire deplores that EMA has waited until 2010 to make this decision in favour of patients, which has been overdue for so many years.
Christophe Kopp
Prescrire staff member
ckopp@prescrire.org